Atezolizumab (MPDL3280A)

Indications

Melanoma (see Melanoma, Melanoma)

  • Clinical Efficacy
    • xxx

Non-Small Cell Lung Cancer (see Lung Cancer, Lung Cancer)

  • Clinical Efficacy
    • POPLAR (Phase 2) Trial of Atezolizumab vs Docetaxel for Previously-Treated Non-Small Cell Lung Cancer (Lancet, 2016) [MEDLINE]: atezolizumab significantly improved survival compared with docetaxel
      • Improvement correlated with PD-L1 immunohistochemistry expression on tumor cells and tumor-infiltrating immune cells, suggesting that PD-L1 expression is predictive of atezolizumab benefit
      • Atezolizumab was well tolerated, with a safety profile distinct from chemotherapy

Pharmacology

Metabolism

  • xxxx

Administration

  • xxxx

Dose Adjustment

  • Hepatic:
  • Renal:

Adverse Effects

Other Adverse Effects

  • xxx
  • xxx
  • xxx

References

  • Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016 Mar 9. pii: S0140-6736(16)00587-0. doi: 10.1016/S0140-6736(16)00587-0 [MEDLINE]
  • PD-L1 in non-small-cell lung cancer: the third target for immunotherapy. Lancet. 2016 Mar 10. pii: S0140-6736(16)00700-5. doi: 10.1016/S0140-6736(16)00700-5 [MEDLINE]